Telmisartan: a different angiotensin II receptor blocker protecting a different population?

Détails

ID Serval
serval:BIB_FBD9ACA9EC30
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Telmisartan: a different angiotensin II receptor blocker protecting a different population?
Périodique
Journal of International Medical Research
Auteur⸱e⸱s
Burnier Michel
ISSN
0300-0605[print], 0300-0605[linking]
Statut éditorial
Publié
Date de publication
2009
Volume
37
Numéro
6
Pages
1662-1679
Langue
anglais
Résumé
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET()) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
Mots-clé
Telmisartan, Angiotensin II Receptor Blocker, Cardiovascular Disease, Cardiovascular Protection, Cardiovascular Risk, Pharmacodynamics, Pharmacokinetics, Left-Ventricular Hypertrophy, Ambulatory Blood-Pressure, To-Moderate Hypertension, Converting Enzyme-Inhibitors, Improves Insulin-Resistance, Gamma-Modulating Activity, Type-2 Diabetic-Patients, End-Point Reduction, High-Risk Patients, E-Deficient Mice
Pubmed
Web of science
Création de la notice
24/03/2010 16:50
Dernière modification de la notice
20/08/2019 17:27
Données d'usage